APEIRON Biologics AG Email Format

Biotechnology ResearchWien, Austria11-50 Employees

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.  

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

✕

Access Insights for APEIRON Biologics AG and Millions of Other Companies

Sign up for full access to APEIRON Biologics AG information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory